Advanced search
Publication Cover
Leukemia & Lymphoma Volume 55, 2014 - Issue 7
Submit an article Journal homepage
881
Views
39
CrossRef citations to date
0
Altmetric
Research Article

Ten-day decitabine as initial therapy for newly diagnosed patients with acute myeloid leukemia unfit for intensive chemotherapy

Bhavana BhatnagarUniversity of Maryland Greenebaum Cancer Center, Baltimore MD, USA;Division of Hematology and Medical Oncology, Department of Medicine, University of Maryland School of Medicine, Baltimore, MD, USA
,
Vu H. DuongUniversity of Maryland Greenebaum Cancer Center, Baltimore MD, USA;Division of Hematology and Medical Oncology, Department of Medicine, University of Maryland School of Medicine, Baltimore, MD, USA
,
Theodore S. GourdinUniversity of Maryland Greenebaum Cancer Center, Baltimore MD, USA;Division of Hematology and Medical Oncology, Department of Medicine, University of Maryland School of Medicine, Baltimore, MD, USA
,
Michael L. TidwellUniversity of Maryland Greenebaum Cancer Center, Baltimore MD, USA
,
Ching ChenUniversity of Maryland Greenebaum Cancer Center, Baltimore MD, USA;Department of Pathology, University of Maryland School of Medicine, Baltimore, MD, USA
,
Yi NingUniversity of Maryland Greenebaum Cancer Center, Baltimore MD, USA;Department of Pathology, University of Maryland School of Medicine, Baltimore, MD, USA
,
Ashkan EmadiUniversity of Maryland Greenebaum Cancer Center, Baltimore MD, USA;Division of Hematology and Medical Oncology, Department of Medicine, University of Maryland School of Medicine, Baltimore, MD, USA
,
Edward A. SausvilleUniversity of Maryland Greenebaum Cancer Center, Baltimore MD, USA;Division of Hematology and Medical Oncology, Department of Medicine, University of Maryland School of Medicine, Baltimore, MD, USA
&
Maria R. BaerUniversity of Maryland Greenebaum Cancer Center, Baltimore MD, USA;Division of Hematology and Medical Oncology, Department of Medicine, University of Maryland School of Medicine, Baltimore, MD, USACorrespondence[email protected]
 show all
Pages 1533-1537 | Received 04 Jul 2013, Accepted 13 Oct 2013, Published online: 04 Feb 2014

Citations (39)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (5)

Binbin Lai, Qitian Mu, YanLi Zhang, Ying Chen, Xiao Yan & Guifang Ouyang. (2021) Outcomes of newly diagnosed acute myeloid leukemia with myelodysplasia related changes and elderly acute myeloid leukemia following decitabine therapy in combination with priming regimen. Hematology 26:1, pages 751-757.
Read now
Bhavana Bhatnagar, Qiuhong Zhao, Alice S. Mims, Sumithira Vasu, Gregory K. Behbehani, Karilyn Larkin, James S. Blachly, William Blum, Rebecca B. Klisovic, Amy S. Ruppert, Shelley Orwick, Christopher Oakes, Parvathi Ranganathan, John C. Byrd, Alison R. Walker & Ramiro Garzon. (2020) Selinexor in combination with decitabine in patients with acute myeloid leukemia: results from a phase 1 study. Leukemia & Lymphoma 61:2, pages 387-396.
Read now
Pasquale Niscola, Benedetta Neri, Gianfranco Catalano, Luciana Morino, Marco Giovannini, Laura Scaramucci, Stefano Fratoni, Nélida Inés Noguera, Iole Cordone & Paolo de Fabritiis. (2017) Decitabine as salvage therapy for primary induction failure of acute myeloid leukemia. Acta Oncologica 56:8, pages 1120-1121.
Read now
James Mccloskey, Jamie Koprivnikar & Stefan Faderl. (2015) Sapacitabine in acute myelogenous leukemia. Expert Opinion on Orphan Drugs 3:12, pages 1461-1468.
Read now
Vu H. Duong, Bhavana Bhatnagar, Dan P. Zandberg, Emily J. Vannorsdall, Michael L. Tidwell, Qing Chen & Maria R. Baer. (2015) Lack of objective response of myelodysplastic syndromes and acute myeloid leukemia to decitabine after failure of azacitidine. Leukemia & Lymphoma 56:6, pages 1718-1722.
Read now

Articles from other publishers (34)

Maximilian Schmutz, Manuela Zucknick, Richard F. Schlenk, Daniel Mertens, Axel Benner, Dieter Weichenhan, Oliver Mücke, Konstanze Döhner, Christoph Plass, Lars Bullinger & Rainer Claus. (2023) Predictive value of DNA methylation patterns in AML patients treated with an azacytidine containing induction regimen. Clinical Epigenetics 15:1.
Crossref
Hussein Awada, Carmelo Gurnari, Zhuoer Xie, Jan Philipp Bewersdorf & Amer M. Zeidan. (2023) What’s Next after Hypomethylating Agents Failure in Myeloid Neoplasms? A Rational Approach. Cancers 15:8, pages 2248.
Crossref
Nicholas J. Short & Hagop Kantarjian. (2022) Hypomethylating agents for the treatment of myelodysplastic syndromes and acute myeloid leukemia: Past discoveries and future directions. American Journal of Hematology 97:12, pages 1616-1626.
Crossref
Maria R. BaerAksinija A. KoganSøren M. BentzenTian Mi, Rena G. LapidusVu H. DuongAshkan EmadiSandrine NiyongereCasey L. O'Connell, Benjamin A. YoungbloodStephen B. Baylin & Feyruz V. Rassool. (2022) Phase I Clinical Trial of DNA Methyltransferase Inhibitor Decitabine and PARP Inhibitor Talazoparib Combination Therapy in Relapsed/Refractory Acute Myeloid Leukemia. Clinical Cancer Research 28:7, pages 1313-1322.
Crossref
Michelina Dargenio, Giuseppe Tarantini, Nicola Cascavilla, Enzo Pavone, Pellegrino Musto, Patrizio Mazza, Lorella Melillo, Domenico Pastore, Attilio Guarini, Caterina Buquicchio, Maria Paola Fina, Vincenzo Federico, Teresa Maria Santeramo, Marina Aurora Urbano, Mariangela Leo, Vera Carluccio, Paola Carluccio, Mario Delia, Daniela Carlino, Carolina Vergine, Vito Pier Gagliardi, Giuseppina Greco, Silvia Sibilla, Mariachiara Abbenante, Giovanni Rossi, Giuseppina Spinosa, Annamaria Mazzone, Lara Aprile, Vincenza de Fazio, Crescenza Pasciolla, Giorgina Specchia & Nicola Di Renzo. (2022) Long-Term Follow-Up of Elderly Patients with Acute Myeloid Leukemia Treated with Decitabine: A Real-World Study of the Apulian Hematological Network. Cancers 14:3, pages 826.
Crossref
Nicholas J. Short, Hervé Dombret, Lionel Adès & Hagop Kantarjian. (2022) The Evolution of Research and Therapy With Hypomethylating Agents in Acute Myeloid Leukemia and Myelodysplastic Syndrome: New Directions for Old Drugs. The Cancer Journal 28:1, pages 29-36.
Crossref
Miriam Saiz-Rodríguez, Jorge Labrador, Beatriz Cuevas, David Martínez-Cuadrón, Verónica Campuzano, Raquel Alcaraz, Isabel Cano, Miguel A. Sanz & Pau Montesinos. (2021) Use of Azacitidine or Decitabine for the Up-Front Setting in Acute Myeloid Leukaemia: A Systematic Review and Meta-Analysis. Cancers 13:22, pages 5677.
Crossref
Kunhwa Kim, Abhishek Maiti, Sanam Loghavi, Rasoul Pourebrahim, Tapan M. Kadia, Caitlin R. Rausch, Ken Furudate, Naval G. Daver, Yesid Alvarado, Maro Ohanian, Koji Sasaki, Nicholas J. Short, Koichi Takahashi, Musa Yilmaz, Guilin Tang, Farhad Ravandi, Hagop M. Kantarjian, Courtney D. DiNardo & Marina Y. Konopleva. (2021) Outcomes of TP53 ‐mutant acute myeloid leukemia with decitabine and venetoclax . Cancer 127:20, pages 3772-3781.
Crossref
Ian M. Bouligny, Vivek Mehta, Scott Isom, Leslie R. Ellis, Rupali R. Bhave, Dianna S. Howard, Susan Lyerly, Megan Manuel, Sarah Dralle, Bayard L. Powell & Timothy S. Pardee. (2021) Efficacy of 10-day decitabine in acute myeloid leukemia. Leukemia Research 103, pages 106524.
Crossref
Vassiliki Mpakou, Aris Spathis, Anthi Bouhla, Efthimia Mpazani, Sotirios Papageorgiou, Konstantinos Gkontopoulos, Eirini Glezou, Thomas Thomopoulos, Periklis Foukas & Vasiliki Pappa. (2021) Synergistic inhibitory effects of low‑dose decitabine in combination with bortezomib in the AML cell line Kasumi‑1. Experimental and Therapeutic Medicine 21:3.
Crossref
Gerwin HulsDana A. ChituThomas PabstSaskia K. KleinGeorg Stussi, Laimonas GriskeviciusPeter J. M. ValkJacqueline Cloos, Arjan A. van de LoosdrechtDimitri BreemsDanielle van Lammeren-VenemaIsabelle van Zeventer, Rinske BoersmaMojca Jongen-LavrencicMartin FehrMels HoogendoornMarkus G. ManzMaaike SöhneRien van Marwijk KooyDries Deeren, Marjolein W. M. van der PoelMarie Cecile LegdeurLidwine TickYves Chalandon, Emanuele Ammatuna, Sabine Blum, Bob Löwenberg & Gert J. Ossenkoppele. (2020) Ibrutinib added to 10-day decitabine for older patients with AML and higher risk MDS. Blood Advances 4:18, pages 4267-4277.
Crossref
Jun H. Choi, James M. Bogenberger & Raoul Tibes. (2020) Targeting Apoptosis in Acute Myeloid Leukemia: Current Status and Future Directions of BCL-2 Inhibition with Venetoclax and Beyond. Targeted Oncology 15:2, pages 147-162.
Crossref
Chenchen Zhao, Bei Jia, Ming Wang, Todd D. Schell, David F. Claxton, W Christopher Ehmann, Witold B. Rybka, Shin Mineishi, Seema Naik, Natthapol Songdej, Jeff M. Sivik, Raymond J. Hohl, Hui Zeng & Hong Zheng. (2019) Multi‐dimensional analysis identifies an immune signature predicting response to decitabine treatment in elderly patients with AML. British Journal of Haematology 188:5, pages 674-684.
Crossref
Valeria Santini & Gert J. Ossenkoppele. (2019) Hypomethylating agents in the treatment of acute myeloid leukemia: A guide to optimal use. Critical Reviews in Oncology/Hematology 140, pages 1-7.
Crossref
Joel M Michalski, Elizabeth R Lyden, Andrea J Lee, Zaid S Al-Kadhimi, Lori J Maness, Krishna Gundabolu & Vijaya Raj Bhatt. (2019) Intensity of chemotherapy for the initial management of newly diagnosed acute myeloid leukemia in older patients. Future Oncology 15:17, pages 1989-1995.
Crossref
Eun-Ji Choi, Je-Hwan Lee, Han-Seung Park, Jung-Hee Lee, Miee Seol, Young-Shin Lee, Young-Ah Kang, Mijin Jeon, Ji Min Woo & Kyoo-Hyung Lee. (2019) Decitabine Versus Intensive Chemotherapy for Elderly Patients With Newly Diagnosed Acute Myeloid Leukemia. Clinical Lymphoma Myeloma and Leukemia 19:5, pages 290-299.e3.
Crossref
Gerwin Huls, Stefan Suciu, Pierre Wijermans, Michal Kicinski & Michael Lübbert. (2019) 10-day vs 5-day decitabine: equivalence cannot be concluded. The Lancet Haematology 6:4, pages e177.
Crossref
Nicholas J Short, Hagop M Kantarjian, Sanam Loghavi, Xuelin Huang, Wei Qiao, Gautam Borthakur, Tapan M Kadia, Naval Daver, Maro Ohanian, Courtney D Dinardo, Zeev Estrov, Rashmi Kanagal-Shamanna, Abhishek Maiti, Christopher B Benton, Prithviraj Bose, Yesid Alvarado, Elias Jabbour, Steven M Kornblau, Naveen Pemmaraju, Nitin Jain, Yvonne Gasior, Mary Ann Richie, Sherry Pierce, Jorge Cortes, Marina Konopleva, Guillermo Garcia-Manero & Farhad Ravandi. (2019) Treatment with a 5-day versus a 10-day schedule of decitabine in older patients with newly diagnosed acute myeloid leukaemia: a randomised phase 2 trial. The Lancet Haematology 6:1, pages e29-e37.
Crossref
Gail J. RobozSumithra J. MandrekarPinkal DesaiKristina LaumannAlison R. WalkerEunice S. WangJonathan E. KolitzBayard L. PowellEyal C. AttarWendy StockClara D. BloomfieldJessica KohlschmidtKrzysztof MrózekDuane C. HassaneLevi GarrawayJudit Jané-ValbuenaMichele Baltay, Adam TracyGuido Marcucci, Richard M. StoneRichard A. Larson. (2018) Randomized trial of 10 days of decitabine ± bortezomib in untreated older patients with AML: CALGB 11002 (Alliance). Blood Advances 2:24, pages 3608-3617.
Crossref
Guillermo Montalban-Bravo & Courtney D DiNardo. (2018) The role of IDH mutations in acute myeloid leukemia . Future Oncology 14:10, pages 979-993.
Crossref
Gail J. Roboz, Hagop M. Kantarjian, Karen W. L. Yee, Patricia L. Kropf, Casey L. O'Connell, Elizabeth A. Griffiths, Wendy Stock, Naval G. Daver, Elias Jabbour, Ellen K. Ritchie, Katherine J. Walsh, David Rizzieri, Scott D. Lunin, Tania Curio, Woonbok Chung, Yong Hao, James N. Lowder, Mohammad Azab & Jean-Pierre J. Issa. (2018) Dose, schedule, safety, and efficacy of guadecitabine in relapsed or refractory acute myeloid leukemia. Cancer 124:2, pages 325-334.
Crossref
F El Chaer, N Holtzman, E Binder, N C Porter, Z N Singh, M Koka, A P Rapoport & A Emadi. (2017) Durable remission with salvage decitabine and donor lymphocyte infusion (DLI) for relapsed early T-cell precursor ALL. Bone Marrow Transplantation 52:11, pages 1583-1584.
Crossref
Rama Nanah, Kristen McCullough, William Hogan, Kebede Begna, Mrinal Patnaik, Michelle Elliott, Mark Litzow & Aref Al-Kali. (2017) Outcome of elderly patients after failure to hypomethylating agents given as frontline therapy for acute myeloid leukemia: Single institution experience*. American Journal of Hematology 92:9, pages 866-871.
Crossref
G Montalban-Bravo, X Huang, E Jabbour, G Borthakur, C D DiNardo, N Pemmaraju, J Cortes, S Verstovsek, T Kadia, N Daver, W Wierda, Y Alvarado, M Konopleva, F Ravandi, Z Estrov, N Jain, A Alfonso, M Brandt, T Sneed, H-C Chen, H Yang, C Bueso-Ramos, S Pierce, E Estey, Z Bohannan, H M Kantarjian & G Garcia-Manero. (2016) A clinical trial for patients with acute myeloid leukemia or myelodysplastic syndromes not eligible for standard clinical trials. Leukemia 31:2, pages 318-324.
Crossref
Hyunsung ParkHaerim ChungJungyeon LeeJieun JangYundeok KimSoo Jeong KimJin Seok KimYoo Hong MinJune-Won Cheong. (2017) Decitabine as a First-Line Treatment for Older Adults Newly Diagnosed with Acute Myeloid Leukemia. Yonsei Medical Journal 58:1, pages 35.
Crossref
Wei Wu, Yan Lin, Lili Xiang, Weimin Dong, Xiaoying Hua, Yun Ling, Haiqian Li, Feng Yan, Xiaobao Xie & Weiying Gu. (2016) Low-dose decitabine plus all-trans retinoic acid in patients with myeloid neoplasms ineligible for intensive chemotherapy. Annals of Hematology 95:7, pages 1051-1057.
Crossref
Ashkan Emadi, Najeebah Bade, Brandi Stevenson & Zeba Singh. (2016) Minimally-Myelosuppressive Asparaginase-Containing Induction Regimen for Treatment of a Jehovah’s Witness with mutant IDH1/NPM1/NRAS Acute Myeloid Leukemia. Pharmaceuticals 9:1, pages 12.
Crossref
Maria Teresa Voso, Francesco Lo-Coco & Luana Fianchi. (2015) Epigenetic therapy of myelodysplastic syndromes and acute myeloid leukemia. Current Opinion in Oncology 27:6, pages 532-539.
Crossref
BINGJIE DING, ZHIXIANG WANG, XUEJIE JIANG, XIAODONG LI, CHUNLI WANG, QINGXIU ZHONG, LING JIANG, MIN DAI, YU ZHANG, QI WEI & FANYI MENG. (2015) Palliative chemotherapy followed by methylation inhibitor in high-risk acute myeloid leukemia: An in vitro and clinical study. Molecular and Clinical Oncology 3:5, pages 1139-1144.
Crossref
Neha Gupta, Austin Miller, Shipra Gandhi, Laurie A. Ford, Carlos E. Vigil, Elizabeth A. Griffiths, James E. Thompson, Meir Wetzler & Eunice S. Wang. (2015) Comparison of epigenetic versus standard induction chemotherapy for newly diagnosed acute myeloid leukemia patients ≥60 years old. American Journal of Hematology 90:7, pages 639-646.
Crossref
Ashkan Emadi, Rawan Faramand, Brandon Carter-Cooper, Seda Tolu, Laurie A. Ford, Rena G. Lapidus, Meir Wetzler, Eunice S. Wang, Arash Etemadi & Elizabeth A. Griffiths. (2015) Presence of isocitrate dehydrogenase mutations may predict clinical response to hypomethylating agents in patients with acute myeloid leukemia. American Journal of Hematology 90:5, pages E77-E79.
Crossref
Gail J. Roboz. (2014) Epigenetic targeting and personalized approaches for AML. Hematology 2014:1, pages 44-51.
Crossref
Eunice S. Wang. (2014) Treating acute myeloid leukemia in older adults. Hematology 2014:1, pages 14-20.
Crossref
Peter H. Wiernik. (2014) Inching toward cure of acute myeloid leukemia: a summary of the progress made in the last 50 years. Medical Oncology 31:8.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.